Piramal Enterprises saw the highest growth of 0.99% in patent filings and no patents were granted in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Piramal Enterprises’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Piramal Enterprises has been focused on protecting inventions in United States(US) with one publication in Q2 2024
The United States(US) Patent Office dominates the patent filings with nearly 100% of filings. The United States(US) patent Office are among the top ten patent offices where Piramal Enterprises is filings its patents..
Roche and Johnson & Johnson could be the strongest competitors for Piramal Enterprises
Patents related to rare diseases lead Piramal Enterprises's portfolio
Piramal Enterprises has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Melanoma related patents lead Piramal Enterprises portfolio followed by metastatic melanoma
Piramal Enterprises has highest number of patents in melanoma followed by metastatic melanoma.
For comprehensive analysis of Piramal Enterprises's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

